Skip to main content

The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer

Tumor Biology volume 37, pages 8657–8664 (2016)Cite this article

Abstract

Macrophages play a critical role in the initiation and progression of various solid tumors. However, their prognostic significance in pancreatic ductal adenocarcinoma (PDAC) is poorly understood. This study investigated the distribution patterns of macrophages in PDAC and possible association with the overall survival (OS). We found significant differences in macrophage density (identified by CD68 and CD163 immunopositivity; p < 0.001 for both) between primary cancer and paired adjacent normal tissues. Most macrophages in cancerous pancreatic tissues were located in the stroma rather than the islets (p = 0.032 and p < 0.001). We also demonstrated that a high total macrophage density (characterized by CD68 immunopositivity) correlated with an absence of jaundice before surgery (p = 0.03) and that a high density of M2 macrophages (characterized by CD163 immunopositivity) in the stroma strongly correlated with the tumors located in the tail and body of the pancreas (p = 0.04). In addition, OS was shorter in patients with high-density M2 macrophage infiltration than in those with low-density M2 macrophage infiltration (p = 0.012). Moreover, multivariate analysis revealed that dense M2 macrophage infiltration into the stroma was an independent prognostic factor for PDAC patients (p = 0.02).

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    CAS  Article  PubMed  Google Scholar 

  4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    CAS  Article  PubMed  Google Scholar 

  5. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60:861–8.

    Article  PubMed  Google Scholar 

  6. Liu Y, Du L. Role of pancreatic stellate cells and periostin in pancreatic cancer progression. Tumor Biol. 2015;36:3171–7.

    CAS  Article  Google Scholar 

  7. Tang D, Gao J, Wang S, Yuan Z, Ye N, Chong Y, et al. Apoptosis and anergy of t cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumor Biol. 2015;36:5617–26.

    CAS  Article  Google Scholar 

  8. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462–72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–55.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. van Furth R. Origin and turnover of monocytes and macrophages; cell kinetics of the inflammatory reaction. Springer; 1989. p. 125–50.

  11. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.

    CAS  Article  PubMed  Google Scholar 

  12. Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, et al. Impact of tumor‐associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012;103:2012–20.

    CAS  Article  PubMed  Google Scholar 

  13. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167:e211–9.

    Article  PubMed  Google Scholar 

  14. An T, Sood U, Pietruk T, Cummings G, Hashimoto K, Crissman J. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. Am J Pathol. 1987;128:52.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 2008;99:1595–602.

    CAS  Article  PubMed  Google Scholar 

  16. Lin EY, Li J-F, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66:11238–46.

    CAS  Article  PubMed  Google Scholar 

  17. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–6.

    CAS  Article  PubMed  Google Scholar 

  18. Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol. 2013;4:210.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Chen SJ, Zhang QB, Zeng LJ, Lian GD, Li JJ, Qian CC, et al. Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in china. Curr Oncol. 2015;22:e11–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, et al. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci. 2015;16:6677–93.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 2012;4:376.

    PubMed  PubMed Central  Google Scholar 

  23. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277–86.

    Article  PubMed  Google Scholar 

  24. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the m2-like macrophage population. Cancer Res. 2014;74:24–30.

    CAS  Article  PubMed  Google Scholar 

  25. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33:119–26.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914–23.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells; cell fusion in health and disease. Springer; 2011. p. 141–50.

  28. Maniecki MB, Møller HJ, Moestrup SK, Møller BK. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology. 2006;211:407–17.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant Nos. 81171887, 91229117, 81502017, 81502018, and 81572315), by Research Grant from Shanghai Hospital Development Center (SHDC12014128), by Songjiang Liandong Program (0702N14002), and in part by the National Key Clinical Discipline Oncology.

Author information

Author notes

    Affiliations

    1. Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 650 New Songjiang Road, Shanghai, 201620, China

      Hai Hu, Jun-Jie Hang, Ting Han, Meng Zhuo, Feng Jiao & Li-Wei Wang

    2. Shanghai Key laboratory of Pancreatic Disease, Shanghai, 201620, China

      Hai Hu, Jun-Jie Hang, Ting Han, Meng Zhuo, Feng Jiao & Li-Wei Wang

    Authors
    1. Hai Hu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jun-Jie Hang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Ting Han
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Meng Zhuo
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Feng Jiao
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Li-Wei Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Feng Jiao or Li-Wei Wang.

    Ethics declarations

    Written informed consent and approval from the Ethics Committees of Shanghai General Hospital were obtained for the use of these clinical materials for research purposes.

    Conflicts of interest

    None

    Additional information

    Hai Hu, Jun-Jie Hang and Ting Han contributed equally to this work.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Hu, H., Hang, JJ., Han, T. et al. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumor Biol. 37, 8657–8664 (2016). https://doi.org/10.1007/s13277-015-4741-z

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-4741-z

    Keywords

    • Immunohistochemistry
    • Macrophage
    • Pancreatic ductal adenocarcinoma
    • Prognosis